Hemab Therapeutics Holdings (COAG) stock

Blood therapies , market cap $1.6B

Therapies for blood coagulation disorders

Market cap $1.6B

$36.02

+4.71%

As of Monday's close · Live for Pro members at the open

Quality Score

Below Average

In its industry

#93of 291

Biotech

Checks firing

4of 14

Trending down

From its high

-35.0%

No 200-day yet

COAG's Quality Score rose 1 point on Mon, Oct 26, to 3. Closed near the day's high.

New listing, trading since May 1, 2026. 123 trading days so far, so 3 of the 14 chart checks wait for more history.

Follow COAG's trial news. Pro members can get an alert when Hemab Therapeutics Holdings files news, and see its trials, share raises, and its CEO's filings.

Get an alert when COAG files news on its trialsSee it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Next2H 2026“…data package as sufficient to proceed to a Phase 3 pivotal trial in GT; Phase 3 initiation planned 2H 2026”Trial start · SEC filing · Aug 11

Why is COAG down?

Down 32% in 3 months, 12% under its 50-day average.

Down more than its industry: the 280 other stocks in it fell a median 13% over the same 3 months.

−1Volatility moves 7.1% a day with no profit or positive free cash flow over four quarters on file

Get an alert when COAG's Quality Score turns up →

Key facts on COAG

Key facts on COAG
Holding it back	Moves 7.1% a day with no profit behind it
Latest filing	8-K, Sep 24 Reported a change of officers or directors

COAG in the news

TodayNo story names it yet.

Tested. Our top-⁠scored stocks returned 2.2x the average stock over the next month. How we tested it

COAG catalysts

Coming up

After its last 2 reports it closed +1.6% on average, higher 1 of 2 times.

3 more coming up and 1 past catalyst since 2026, with sizes and sources, for Pro members.Get in free →

What's next for COAG, and how long its cash lasts

Next step the company has named

2H 2026“sutacimig clinical data package as sufficient to proceed to a Phase 3 pivotal trial in GT; Phase 3 initiation planned 2H 2026”Trial start · SEC filing · Aug 11

What it means: when a trial begins, or reaches the stage the company named.

A trial underway: HMB-002 in Participants With Von Willebrand DiseasePhase 1/2 · Recruiting · 108 people · main data estimated Jul 2027 · NCT06754852

3 more trials, 1 more milestone and 5 filings, for Pro members.

Cash runway Jun 30 balance sheet

$457M in cash

Fewer than four quarters of cash flow are on file.

What it means: a runway is counted only when each of the last four quarters used cash. The company's estimate is “into 2029” (8-K, Aug 11).

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

No shelf registration or at-the-market program on file in the last three years.

For Pro members: 1 raise and its amount, and the share count against a year ago.

Insiders

Director RA CAPITAL MANAGEMENT, L.P. bought 2,840,429 shares on May 6.

From Form 4: open-market buys and sales only.

For Pro members: every trade.

Get an alert when COAG files news on its trialsSee it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 15 daysANDA decisionIn 15 days · ANDA decisionNRXPNRX PharmaceuticalsPreservative-free ketamineNRXPNRX Pharmaceuticals · $104MPreservative-free ketamineA generic, under FDA review (GDUFA)
In 27 daysFDA decisionIn 27 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $356MDeramiocelFDA decision due (PDUFA)
In 27 daysFDA decisionIn 27 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $933MMolgramostimFDA decision due (PDUFA)

10 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 168 dates, ranked →

Here is what Pro members see.

The same page for Pro members, on AMD
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on COAG and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

COAG has 4 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on COAG, and all 14 on every stock.Get in free →

COAG RSI today: 54.9, below its 50-day average

Not scored

Not in the Quality Score: over 20 years of tests, 2006 to 2026, they added no edge.

RSI 1454.9
Above 50, below 70.
MACD (12, 26, 9)Above signal
Crossed above its signal line 10 sessions ago.
50-day average$38.85
The price is 7.3% below it.
200-day average
Not enough history yet.
50/200 cross
Not enough history yet.
ADX 1425.9
25 or more, with +DI above -DI.
Support$29.54
Swing low from Jul 7, 18.0% below the price.
Resistance$38.87
Swing high from Jun 29, 7.9% above the price.
High since listing$55.42
From Aug 14, 53.9% above the price.
Low since listing$23.00
From May 11, 36.1% below the price.
Chart patternNone
No triangle, channel, or wedge in the last year.
Bollinger Bands (20, 2)Inside
The bands run from $27.50 to $36.04.
Volume0.7x
Against its 20-day average, for the time of day.

The deep dive on COAG

What it does and how it makes money1 findingFor Pro members1 finding on what COAG does and how it makes money, for Pro members
Where it stands1 finding$457M in cash and short-term investments on Jun 30, 2026.Balance sheet of Jun 30, 2026, filed Aug 11, 2026
Who holds and trades it3 findingsFor Pro members3 findings on who holds and trades COAG, for Pro members

4 more findings on COAG, each with its source, for Pro membersGet in free →

How COAG ranks in Biotech

COAG is #93 of 291 by Quality Score.

How COAG ranks in Biotech
1	HALOHalozyme Therapeutics	9/14	21
2	AMRXAmneal Pharmaceuticals	9/14	20
3	RIGLRigel Pharmaceuticals	9/14	19
	CLDXCelldex Therapeutics		Open for its score
	CLYMClimb Bio		Open for its score
	COGTCogent Biosciences		Open for its score
	COLLCollegium Pharmaceutical		Open for its score
93	COAGHemab Therapeutics	4/14	3

When does COAG report earnings, and what happens after?

Expected to report Mon Nov 16, before the open (in 21 days). Expected.

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What COAG reported on Aug 11, 2026

The quarter

The figures are not read from the release yet.

“The decrease in net loss per share primarily reflects the increase in weighted-average shares outstanding during the three months ended June 30, 2026 following the Company’s initial public offering and the subsequent conversion of preferred stock into common stock in May 2026.”

The filing on EDGAR

Where the sales came from

COAG's results filing gives no sales by line in a table we read.

The outlook

No outlook figures read from this release.

In the company's words

“The increase primarily reflects net proceeds of $317.2 million from the Company’s initial public offering completed in May 2026, partially offset by cash used in operating activities.”

From its results filing (SEC filing · Aug 11)

2 more sentences, for Pro members.

The numbers

Market value: $1.6B; today

No analyst estimates on Breakaway: every figure here is filed.

The whole report on COAG: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.Get in free →

-0.6%+3.8%

May 21Aug 11

Reported	When	Gap	Reaction	5 sessions
Aug 11, 2026Before open	Before open	0.0%	+3.8%	+7.5%
May 21, 2026Before open	Before open	-1.5%	-0.6%	+5.8%

COAG closed higher after 1 of its last 2 reports.

COAG share count over time

Shares: 31.8 times the count a year ago (to Jun 30).

Shares of COAG outstanding, as filed
Shares outstanding	As of
46.7M	Jul 31, 2026
46.7M	May 8, 2026

Offerings, shelves, and splits of COAG, from its filings
From its filings	Filed
Raised $301.5M in a sale of shares, about 19% of its market value	May 1, 2026
Registered shares for sale (S-1)	Apr 10, 2026

Who is trading COAG

COAG insider trades

2 insiders bought $55.5M across 16 filings in the last 6 months. No open-⁠market sales on record. The newest:

BuyRa Capital Management, L.P.$1.5M10% ownerat $24.98 on Jun 16, filed Jun 17

BuyRa Capital Management, L.P.10% owner$1.5Mat $24.98 on Jun 16, filed Jun 17

All 16 insider filings on COAG from the last six months, for Pro members.Get in free →

All COAG insider trades

COAG's officers and directors

Officers and directors with a Form 4 in the last 12 months.

John MaraganoreDirector

See insider trades by person

Which ETFs hold COAG?

In ETFs: COAG is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Hemab Therapeutics Holdings

Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.

Cambridge, MAhemab.com

Listed on Nasdaq on May 1, 2026, and is 100% above its $18 offer price now. Its IPO filing and first days

COAG's score card

Hemab Therapeutics Holdings (COAG): Quality Score 3, Below Average, #93 of 291 in Biotech, with its price, on Breakaway — The picture a link to this page shows when it is shared.

Pro members see every line of every stock's score.

What would turn COAG's score around: 3 things
3 more filings explained, a plain line each
Real-⁠time prices, no delay

BreakawayJun 17Ra Capital Management, L.P. bought COAG$1.5M at $24.98, filed Jun 17

Alerts are optional.

See COAG's 14 chart checks

See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

Straight Answers

As of Oct 26, 2026: COAG's Quality Score is 3 (Below Average), #93 of 291 in Biotech. Insiders bought $55.5M in the last 6 months (Form 4).

Is COAG a good stock to buy? What its Quality Score says

COAG scores 3 today, which Breakaway calls Below Average. It is #93 of 291 in Biotech by Quality Score, with 4 of 14 chart checks firing. Down 32% in 3 months, 12% under its 50-⁠day average. Shares: 31.8 times the count a year ago (to Jun 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is COAG's Quality Score?

COAG scores 3 today, which Breakaway calls Below Average (0 to 5). That is #93 of 291 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind COAG's 3.

Are insiders buying COAG?

2 insiders bought $55.5M across 16 filings in the last 6 months. No open-⁠market sales on record. The newest is Ra Capital Management, L.P., 10% owner, who bought $1.5M on Jun 16. Every filing, with the scored weight, for Pro members.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.